Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 681 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable... February 9, 2026 Inpatient Mammography May Help Solve Issue of Low Screening Rates, Especially... July 12, 2021 Mouse Study Points to Strategy for Preserving Bone During Chemotherapy February 25, 2020 Assessment of Patients’ Perspective on the Consequences of the COVID-19 Pandemic... July 16, 2020 Load more HOT NEWS EMA Recommends Extension of Indications for Olaparib Stimulating the Immune System Shrinks Some Slow-Growing Lymphomas FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease Can Chemotherapy Drugs Be Designed to Avoid Side Effects?
